drugset / Trial / NCT04247815

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

NCT04247815

Phase 2 Completed 25 enrolled Aclaris Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2 study to investigate the safety, tolerability, PK, and PD of ATI-450 plus methotrexate versus methotrexate alone in patients with moderate to severe RA.

Timeline

Start
2020-03-16
Primary completion
2021-02-04
Completion
2021-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Zunsemetinib Small molecule 50 mg Oral
Background Methotrexate Small molecule 7.5 mg
Background Methotrexate Small molecule 25 mg

Indications